-
Blog BLOG
-
Product Center BRAND DYNAMICS
-
Investor INVESTOR RELATIONS
-
Contact Us CONTACT
-
Supervise SUPERVISION
Jiankangyuan's anti-influenza drug application for market listing
Published Time:
2024-08-12
On August 12, the CDE website showed that the marketing application for the influenza drug TG-1000 capsules of Health Spring has been accepted.

This year In April, Health Spring announced that the multicenter Phase III clinical trial of TG-1000 capsules for the treatment of uncomplicated influenza A and B acute infections in patients aged 12 years and older without complications had met its primary endpoint, and stated that it would communicate with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in the near future regarding the marketing application for TG-1000 capsules for the treatment of influenza, to advance the listing process of TG-1000 capsules.
TG-1000 is a first-class innovative anti-influenza drug, a novel cap-dependent endonuclease inhibitor, originally developed by Taiji Pharmaceutical and Taiji Bio. Early research data showed that TG-1000 has the characteristics of rapid onset, long viral suppression time, good tolerance, and oral administration unaffected by food, and can effectively inhibit both influenza A and B viruses.
In September 2023, Health Spring, as the applicant, and the First Affiliated Hospital of Guangzhou Medical University, as the leading unit, launched a Phase III clinical trial (n=752) of TG-1000 capsules for the treatment of influenza. This study is a multicenter, randomized, double-blind clinical trial, with the primary endpoint being the time to resolution of all influenza symptoms within 15 days of treatment.
Preliminary statistical analysis results show that, The median time to resolution of all influenza symptoms in the TG-1000 group and the placebo group were 60.9 hours and 87.9 hours, respectively, meeting the primary efficacy endpoint and showing a statistically significant difference (P<0.0001). In terms of safety, the incidence of adverse events (AEs) in the TG-1000 group was similar to that in the placebo group, with no deaths or drug-related serious adverse reactions.
This article is transferred from: Pharmaceutical Cube Info
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
Sorry,当前栏目暂无内容!
您可以查看其他栏目或返回 首页
Sorry,The current column has no content!
You can view other columns or return Home